Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Enhancing Immunogenicity in NRAS-Mutant Melanoma Via Autophagy Modulation: A Clinical and Mechanistic Study.

NCT07750067 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07750067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07750067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Enhancing Immunogenicity in NRAS-Mutant Melanoma Via Autophagy Modulation: A Clinical and Mechanistic Study.
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Recruiting
Start date
April 1, 2026
Completion date
July 28, 2030
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma metastatic, nras mutation